<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02660476</url>
  </required_header>
  <id_info>
    <org_study_id>JIRB: 14-0032. MRC: #14461/14</org_study_id>
    <nct_id>NCT02660476</nct_id>
  </id_info>
  <brief_title>Qatar Universal Diabetes Outcomes (QUDOS) Study</brief_title>
  <acronym>QUDOS</acronym>
  <official_title>Qatar Universal Diabetes Outcomes (QUDOS) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Cornell Medical College in Qatar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hamad Medical Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Cornell Medical College in Qatar</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      QUDOS is a cross-sectional population study aiming to answer key questions about diabetes and&#xD;
      its complications in Qatar as well as identify factors associated with the development and&#xD;
      progression of diabetes complications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      QUDOS aims to gain a better understanding of diabetes in primary and secondary care over a&#xD;
      period of 24 months.&#xD;
&#xD;
      A range of patients with diabetes will be sampled (including those with Type 1 diabetes as&#xD;
      this group is under-studied in Qatar). This will be important in designing appropriate&#xD;
      intervention plans that will improve diabetic patients' health conditions to prevent or delay&#xD;
      the onset of complications and will provide a strong foundation for longitudinal study.&#xD;
&#xD;
      The broad objectives of the study are:&#xD;
&#xD;
      QUDOS 1: Aims to recruit 1,700 diabetic patients (including 200 with type 1 diabetes mellitus&#xD;
      (independent of healthcare setting)) attending the hospitals and primary care and to collect&#xD;
      the following data:&#xD;
&#xD;
        -  Demographics: age, sex, ethnicity, socio-economic background, smoking status;&#xD;
&#xD;
        -  Anthropometrics: vital signs, height, weight, body fat percentage, fat mass, neck and&#xD;
           waist circumference;&#xD;
&#xD;
        -  Medical History: medications, complications, comorbidities, latest HbA1c and lipid&#xD;
           profiles and family medical history;&#xD;
&#xD;
        -  Routine laboratory data;&#xD;
&#xD;
        -  Lifestyle: diet, physical activity,;&#xD;
&#xD;
        -  Sleep: quality and daytime sleepiness;&#xD;
&#xD;
        -  Cognition and Mental Health: depression, anxiety, stress and memory;&#xD;
&#xD;
        -  Diabetes microvascular complications: diabetic neuropathy, urine albumin/creatinine&#xD;
           ratio; routine retinal screening data.&#xD;
&#xD;
        -  Gut microbiome from a stool sample&#xD;
&#xD;
      QUDOS 2: To further characterise 500 patients, from the total 1500 patients with T2DM&#xD;
      recruited in QUDOS 1, who accept to continue with QUDOS 2 (a more detailed study and&#xD;
      assessment).&#xD;
&#xD;
      This phase aims to concentrate on the following aspects:&#xD;
&#xD;
        -  Obstructive sleep apnoea;&#xD;
&#xD;
        -  Sleep duration and quality;&#xD;
&#xD;
        -  Diet;&#xD;
&#xD;
        -  Objective physical activity;&#xD;
&#xD;
        -  Stress;&#xD;
&#xD;
        -  Quality of Life;&#xD;
&#xD;
        -  Depression and anxiety;&#xD;
&#xD;
        -  Perceived control of health;&#xD;
&#xD;
        -  Detailed neuropathy screening;&#xD;
&#xD;
        -  Cardiovascular function;&#xD;
&#xD;
        -  Cognitive function;&#xD;
&#xD;
        -  Biological samples.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diabetes Complications (Nephropathy, Neuropathy, Retinopathy)</measure>
    <time_frame>Baseline (Cross-Sectional)</time_frame>
    <description>Our primary analyses will be conducted to explore the potential cross-sectional relationships amongst proposed factors related to type 2 diabetes complications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mental Health</measure>
    <time_frame>Baseline (Cross-Sectional)</time_frame>
    <description>To assess the relationships between T2DM and depression through questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep and sleep related breathing disorders</measure>
    <time_frame>Baseline (Cross-Sectional)</time_frame>
    <description>To assess the relationships between T2DM and sleep disordered breathing, sleep duration and sleep quality through a home sleep study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical activity</measure>
    <time_frame>Baseline (Cross-Sectional)</time_frame>
    <description>To assess the relationships between T2DM and physical activity using an Actiwatch</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1700</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>QUDOS 1</arm_group_label>
    <description>Aims to recruit 1,700 diabetic patients (including 200 with type 1 diabetes mellitus (independent of healthcare setting)) attending the hospitals and primary care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QUDOS 2</arm_group_label>
    <description>To further characterise 500 patients, from the total 1500 patients with T2DM recruited in QUDOS 1, who accept to continue with QUDOS 2 (a more detailed study and assessment).</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, urine, saliva and stool samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients 18-70 years old with diabetes, who are a resident in Qatar or born in one of&#xD;
        the MENA countries with family originating from MENA countries, will be recruited from one&#xD;
        of the following sites:&#xD;
&#xD;
          -  Primary health care centers&#xD;
&#xD;
          -  Hamad General Hospital&#xD;
&#xD;
          -  Al-Wakra Hospital&#xD;
&#xD;
          -  Al-Khor Hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Type 1 and Type 2 diabetes mellitus;&#xD;
&#xD;
          2. Male or Female;&#xD;
&#xD;
          3. Resident in Qatar;&#xD;
&#xD;
          4. MENA birthplace and family origin;&#xD;
&#xD;
          5. 18-70 years old;&#xD;
&#xD;
          6. Capable to give informed consent and complete the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Known pregnancy or planning pregnancy during the duration of study; 2. Congenital&#xD;
        disorders; 3. Terminal illness; 4. Enrolled in a clinical trial involving medication; 5.&#xD;
        Uncontrolled mental illness preventing participation; 6. Those who have already experienced&#xD;
        a definitive microvascular complication:&#xD;
&#xD;
        i. End-stage renal disease; ii. Major amputation; iii. Blindness.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shahrad Taheri, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Cornell Medical College in Qatar</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shahrad Taheri, PhD</last_name>
    <phone>(+974) 4492 8998</phone>
    <email>szt2004@qatar-med.cornell.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Odette Chagoury, PhD</last_name>
    <phone>(+974) 4492 8439</phone>
    <email>olc2004@qatar-med.cornell.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Weill Cornell Medicine Qatar</name>
      <address>
        <city>Doha</city>
        <country>Qatar</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Odette Chagoury, PhD</last_name>
      <phone>(+974) 4492 8439</phone>
      <email>olc2004@qatar-med.cornell.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>Qatar</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 20, 2015</study_first_submitted>
  <study_first_submitted_qc>January 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2016</study_first_posted>
  <last_update_submitted>July 26, 2020</last_update_submitted>
  <last_update_submitted_qc>July 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diet</keyword>
  <keyword>Middle East and North Africa country</keyword>
  <keyword>Health</keyword>
  <keyword>Complication</keyword>
  <keyword>Cardiovascular disease</keyword>
  <keyword>Obesity</keyword>
  <keyword>Stress</keyword>
  <keyword>Obstructive Sleep Apnoea (OSA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

